Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.

Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.

<h4>Background</h4>Docetaxel is an established first-line therapy to treat metastatic castration-resistant prostate cancer (mCRPC). Recently, abiraterone and cabazitaxel were approved for use after docetaxel failure, with improved survival. National Institute for Health and Clinical Exce...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lixian Zhong, Vickie Pon, Sandy Srinivas, Nicole Nguyen, Meghan Frear, Sherry Kwon, Cynthia Gong, Robert Malmstrom, Leslie Wilson
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2013
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/4604469ff4ee41d0af833205905effe0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares